Single center, double-blind, randomized, placebo-controlled, two-period/two-treatment crossover, proof-of-mechanism study investigating the effect of miglustat on the nasal potential difference in adult patients with cystic fibrosis homozygous for the F508del mutation
Phase of Trial: Phase II/III
Latest Information Update: 21 Mar 2018
Price : $35 *
At a glance
- Drugs Miglustat (Primary)
- Indications Cystic fibrosis
- Focus Pharmacodynamics; Proof of concept
- Acronyms MIGLUSTAT-CF
- 31 Aug 2018 Biomarkers information updated
- 16 Mar 2018 Status changed from recruiting to completed.
- 31 Jul 2016 Planned End Date changed from 1 Aug 2017 to 1 Jan 2018.